Turnstone Biologics Corp. Research and Development Expense
Turnstone Biologics Corp. reported Research and Development Expense of $4.36 million for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-09.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2025-05-09
- Turnstone Biologics Corp. research and development expense for the quarter ending 2025-03-31 was $4.36M, a 72.41% decline year-over-year.
- Turnstone Biologics Corp. research and development expense for the quarter ending 2024-12-31 was $8.16M, a 39.37% decline year-over-year.
- Turnstone Biologics Corp. research and development expense for the quarter ending 2024-09-30 was $14.42M, a 1.78% increase year-over-year.
- Turnstone Biologics Corp. research and development expense for the quarter ending 2024-06-30 was $17.73M, a 3.12% increase year-over-year.
- Turnstone Biologics Corp. research and development expense for fiscal 2024 was $56.10M, a 7.25% decline from fiscal 2023.
- Turnstone Biologics Corp. research and development expense for fiscal 2023 was $60.49M, a 30.23% decline from fiscal 2022.
- Turnstone Biologics Corp. research and development expense for fiscal 2022 was $86.70M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2025-03-31 | $4.36M 10-Q · filed 2025-05-09 | $12.52M derived: sum of 2 quarters · filed 2025-05-09 | $26.94M derived: sum of 3 quarters · filed 2025-05-09 | $44.67M derived: sum of 4 quarters · filed 2025-05-09 |
| 2024-12-31 | $8.16M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $22.58M derived: sum of 2 quarters · filed 2025-03-31 | $40.31M derived: sum of 3 quarters · filed 2025-03-31 | $56.10M 10-K · filed 2025-03-31 |
| 2024-09-30 | $14.42M 10-Q · filed 2024-11-12 | $32.15M derived: sum of 2 quarters · filed 2024-11-12 | $47.94M 10-Q · filed 2024-11-12 | $61.40M derived: sum of 4 quarters · filed 2025-05-09 |
| 2024-06-30 | $17.73M 10-Q · filed 2024-08-14 | $33.52M 10-Q · filed 2024-08-14 | $46.98M derived: sum of 3 quarters · filed 2025-05-09 | $61.15M derived: sum of 4 quarters · filed 2025-05-09 |
| 2024-03-31 | $15.79M 10-Q · filed 2025-05-09 | $29.25M derived: sum of 2 quarters · filed 2025-05-09 | $43.42M derived: sum of 3 quarters · filed 2025-05-09 | $60.61M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $13.46M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $27.63M derived: sum of 2 quarters · filed 2025-03-31 | $44.82M derived: sum of 3 quarters · filed 2025-03-31 | $60.49M 10-K · filed 2025-03-31 |
| 2023-09-30 | $14.17M 10-Q · filed 2024-11-12 | $31.36M derived: sum of 2 quarters · filed 2024-11-12 | $47.03M 10-Q · filed 2024-11-12 | $67.25M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $17.19M 10-Q · filed 2024-08-14 | $32.86M 10-Q · filed 2024-08-14 | $53.08M derived: sum of 3 quarters · filed 2024-08-14 | $74.33M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $15.67M 10-Q · filed 2024-05-13 | $35.88M derived: sum of 2 quarters · filed 2024-05-13 | $57.13M derived: sum of 3 quarters · filed 2024-05-13 | $83.67M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $20.21M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | $41.47M derived: sum of 2 quarters · filed 2024-03-22 | $68.00M derived: sum of 3 quarters · filed 2024-03-22 | $86.70M 10-K · filed 2024-03-22 |
| 2022-09-30 | $21.25M 10-Q · filed 2023-11-13 | $47.79M derived: sum of 2 quarters · filed 2023-11-13 | $66.49M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $26.54M 10-Q · filed 2023-09-01 | $45.24M 10-Q · filed 2023-09-01 |